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Polycystic ovarian syndrome is one of an important gynecologic disorder that attracts the attention of many 
scientists about its etiology, diagnosis and treatment. 
It is characterized by enlargement of the ovary, many macroscopic and microscopic changes, with disturbance of 
menstruation and infertility. 
Polycystic ovarian syndrome is a multifactorial disorder of unclear etiology. Its diagnosis depends on many 
criteria.  
Many lines of treatment are used which give different responses. 
Aim of study: 
Follow up the treatment of polycystic ovarian syndrome with metformin and anastrozole through morphological, 
morphometric and histological studies. 
Materials and methods: 
Twenty-one day old female rats had been involved in this study. Forth of them received nothing and considered 
as a control group while the remaining received testosterone to induce polycystic ovarian syndrome. The animals 
with polycystic ovary had been divided into three subgroups; the first one received nothing, while the second one 
treated with metformin and the last subgroup received anastrozole as a therapy. 
The morphological, morphometric and histological studies of each subgroups had been demonstrated and 
comparison between the results obtained of metformin and anastrozole treated subgroups had been analyzed. 
Result: 
The result collected from metformin treated subgroup revealed response to treatment, however, this response 
was inferior to the response of this syndrome to anastrozole. This was observed according to the morphological, 
morphometric and histological studies. 
Discussion: 
Metformin reduces insulin level in the blood which acts directly or systemically on the ovarian tissue to reduce 
androgen production, which in turn, improves the physiological cycle of sexual hormones. However, this 
improvement (reflected by macroscopic and microscopic results) did not approximate the normal value as 
anastrozole did. Anastrozole acts as aromatase enzyme inhibitor, therefore, inhibits aromatization of androgen 
into estrogen. This returned the hormonal cycle to almost normal status.                     
 
1. Introduction 
Polycystic ovarian syndrome (PCOS) is one of the commonest endocrine and gynecological disorders affecting 
women during their reproductive life. It is characterized by enlargement of the ovary, increased ovarian follicular 
cyst number, failure of ovulation, infrequent or absence of menstrual cycle with infertility (Knochenhauer et al, 
1998; Young, 1991). 
The etiology of PCOS, although controversial, is still unclear till now (Ehrmann, 2005). However, there are 
many theories and concepts that may approximate the possibility of the explanation of the etiology of PCOS. 
These are: 
1. There is significant cellular resistance to the circulating insulin, whether in obese or non-obese PCOS 
women (Venkatesan et al, 2001). 
2. Hormonal imbalance: which is considered to be one of the most prominent features of PCOS, in the 
form of androgen excess, LH/FSH imbalance, and disturbance of serum estrogen level (Marx  and 
Metha, 2003). 
3. Genetic factor, since the syndrome could run in families (Fauser et al, 2011; Diamanti-Kandarakis et al, 
2006). 
4. Environmental factors, involving ethnic factor, race, and other environmental causes (Kauffman et al, 
2002). 
5. Inflammatory causes: patients with PCOS are more liable to have high levels of c-reactive protein, with 
disturbances in their immune response (Dehdashtihaghighat et al, 2013). 
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6. Developmental fetal abnormality (Tyndall et al, 2012; Walters et al, 2012). 
The prevalence of PCOS is about 18% of women (although, 70% are undiagnosed previously) (March et al, 
2010). Interestingly, PCOS affects obese women about 5-6 times more than that of non-obese ones (Alvarez-
Blasco et al, 2006; Azziz et al, 2005). 
The diagnosis of PCOS depends on many criteria, these are: 
1- National Institute for Health (NIH) criteria (Zawadzki and Dunaif, 1992). 
2- Rotterdam criteria (The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 
2004). 
3- Androgen Excess PCOS Society criteria (Azziz et al, 2009). 
The main macroscopical changes, that could be detected in the PCOS, are enlargement of the ovary 
(when the ovarian size is larger than the average normal one by 10 ml3, it is considered as a PCOS criterion) 
(The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004). The ovarian cortex 
appears smooth, whitish-gray in color, with many subcortical cysts (0.5-1.5 cm in diameter) leading to coarse 
irregular outline surface (Ellenson & Pirog, 2010). 
Microscopically, the ovary in PCOS reveals the following changes; hyperatrophy of theca interna, 
antral enlargement due to progressive follicular fluid accumulation which results, simultaneously, in 
degeneration of granulosa cells leading to thinning of the wall of the cyst. Besides , the theca cellular layer that 
surrounds the follicle is significantly thinner than that seen in normal ovary. Corpora lutea are scarcely present. 
Besides, hypercellular ovarian stroma and enlargement of central stroma are the characteristic findings in this 
disorder (Ellenson and Pirog, 2010; Chang, 2007).  
The strategy for treatment of PCOS follows general line and specific one (Moran et al, 2009). The 
general line includes weight loss, avoiding weight gain, exercise, besides psychological therapy. 
The specific treatment includes drugs therapy. One of these drugs is metformin (Tang et al, 2010), 
which is principally used in the treatment of type 2 diabetes mellitus. However, metformin is widely used in 
treatment of PCOS, mainly through its effect in reducing circulating insulin in hyperinsulinemia and even in 
patients with normal insulin level in their blood (Ehrmann, 2005). Clomiphene citrate, an estrogen receptor 
blocker, has been used to induce ovulation in PCOS for a long time. However, one of its drawback is the anti-
estrogenic effects on the endometrial & cervical mucosae, which can lead to the failure of the pregnancy. This 
side effect makes clomiphene citrate is out of argument in the treatment of PCOS nowadays (Casper and 
Mitwally, 2012). 
Other group of drugs, used in the treatment of PCOS, is aromatase enzyme inhibitors. Anastrozole is 
an example of aromatase inhibitors. It is a non-steroidal drug used mainly for the treatment of the breast cancer 
in postmenopausal women. This drug inhibits aromatase enzyme action, preventing the conversion of androgen 
into estrogen and hence, blocking estrogen production also blocks the action of estrogen receptors. However, it 
does not have the side effect of clomiphene citrate on the pregnancy (Sioufi et al, 1997). 
 
2. Aim of the Study 
Morphological, morphometric, and histological comparison between the effects of metformin and anastrozole on 
the ovary of the induced PCOS in rat as they are the two main therapeutic agents in the treatment of induced 
PCOS in rat. 
 
3. Materials and Methods 
Norway albino rats had been chosen in this study. They were kept under optimum conditions throughout the 
experiment, regarding temperature, light, and food. 
Eight [8] mature male rats and eight [8] mature female rats had been collected. Each couple had been 
kept in one cage separately. After mating, pregnancy, and near delivery, the males were separated from the 
females.  
The outcome of deliveries was forty [40] offspring. Twenty eight [28] of the offspring were females. 
The age of the new born rats had been calculated till reaching 21 days old. At this age, twenty one premature 
female rats had received 1 mg/100 g body weight/day of testosterone propionate (Sustanon “250” mg, 1 ml 
ampoule, N.V. Organon Oss Holland) daily for 28 days (Waltersw et al, 2012). The route of administration of 
testosterone was subcutaneous injection in the dorsum of the neck of the rat (Beloosesky et al, 2004). The 
remaining 7 premature females received subcutaneous injections of sesame oil for 28 days and considered as a 
control group. 
After testosterone treatment, the 28 female rats were divided into groups and treated with different 
drugs as demonstrated in table-1: 
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Table-1: Grouping of female rats, involved in this experiment, with their different treatments 








Number 7 7 7 7 
Treatment received Received nothing Received 
nothing 
Treated with metformin 
(Glucophage, 500 mg. 
tablet Merk Serono) 
Treated with anastrozole 
(Arimidex 1 mg. tablet 
AstraZeneca) 
Dose and rout of 
administration 
  20 mg/100 gm body 
weigh/day (Di Pietro et 
al, 2014; Kabiri et al, 
2014). The dose had 
been given orally after 
dissolving the grinded 
tablet in the drinking 
water.  
15 µg/kg body 
weight/day (Shirai et al, 
2009). The dose had 
been given orally after 
dissolving the grinded 




  5 weeks 5 weeks 
  TP: testosterone propionate, MET: metformin, ANA: anastrozole. 
During the last week of treatment, all the animals involved in this study had been exposed daily to 
vaginal smears to determine the phase of estrus cycle, since the animals had to be scarified during the pro-estrus 
phase. 
Following anesthesia, both ovaries had been excised and removal of the surrounding adipose tissue had 
been performed. 
The ovaries had been weighed, their size measured, then examined by naked eye (sometimes aided 
with a magnifying lens) to study the morphology of the ovary. The measurement of the ovarian size had been 
performed through putting the ovary inside a graduated cylinder (10 ml volume) filled with normal saline. The 
excess of fluid (before and after putting the ovary inside the graduated cylinder) had been aspirated and 
measured by using another 5 ml empty graduated cylinder. Then the ovaries had been examined using dissecting 
microscope, connected to 10 mega pixel digital camera to study the morphometry of the ovary. 
After that, the ovary had been incubated in 10% formalin, then incubated in paraffin. Sectioning of the 
paraffinized ovary had been done, then the sections had been stained with hematoxyllin and eosin for 
histological examination. 
During histological (microscopical) examination, the following histological parameters had been taken 
in consideration: 
- Number of primary follicles 
- Number of secondary and mature follicles 
- Number of corpora lutea 
- Number of large cystic follicles 
- Number of small cystic follicles 
- Number of cellular layers of theca interna  
- Percentage of interstitial glands to the total stromal area. 
Statistical analysis of the results obtained had been done using PASW statistics software (2009). The results 
were presented as measures of mean + standard error of mean at 95% confidence. Independent t-test and one-
way ANOVA were used to compare between the different groups of the experimental animals.  
Note: p-value < 0.05 : statistically significant 
           p-value < 0.01 : highly statistically significant   
 
4. Results 
Regarding the ovaries of the control animals, they revealed morphological, morphometric, (fig. 1-a) and 
histological features of the normal ovaries. 
The experimental animal subgroups revealed the following results:- 
4.1. Morphological and morphometric result 
• Subgroup-I (TP-treated subgroup only): 
The ovary of this group appeared smaller than that of the control one, with rounded, smooth, and 
whitish surface. Under dissecting microscope, the ovary revealed smooth rounded outline, with 
pale yellowish-white colored cortex due to small, scanty numbers of blood vessels.  
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It could not possible to see corpus luteum. Multiple large cysts filled with fluid were detected 
scattered underneath thick ovarian cortex causing slight bulging of ovarian surface (fig. 1-b). 
• Subgroup-II (MET-treated group): 
The ovary of this group was still smaller and lighter in weight than that of control one and ANA-
treated subgroup, but slightly larger than TP-treated subgroup ovary.    
Morphological and morphometric examination demonstrated the same picture of TP-treated 
ovaries. However, the large cystic follicles appeared to be smaller and not bulging beyond the 
ovarian surface, giving the ovarian outline a contour smoother than that of TP-treated ovaries (fig. 
1-c). 
• Subgroup-III (ANA-treated group): 
 
Generally, the features of the ovaries of this group were closer to those of the control one. The ovarian 
weight of this group was heavier significantly (p < 0.05) than that of TP-treated subgroup and that of MET-
treated groups. Besides, the size of the ovaries returned approximately to the normal ovarian size, yet, it was 
larger than the ovarian size of the MET-treated group. The color of the ovary is dark red, while the ovarian 
outline was obviously irregular to a degree that the general oval-shaped ovary had been distorted. 
Examination of the ovary under dissecting microscope elicited the following: ovarian surface was 
highly lobulated with large numbers of ovarian follicles of variable sizes, bulging out of the ovarian surface. The 
examination revealed also multiple dark red corpora lutea with prominent network of blood vessels. Both 
findings are responsible for the dark colored ovarian surface (fig. 1-d). 
 
4.2. Histological Features: 
Figure 1: Gross ovarian appearance of control group (a), TP-treated group (b), MET-treated group (c), and ANA-
treated group (d). Note the larger size, lobulated surface, red color and rich vasculature in the control and ANA-
treated groups and the smaller size, smooth surface, pale color and poor vasculature in the TP-treated and MET-
treated groups. U: uterus, T: uterine tube, F: fat, OF: ovarian follicles, OC: ovarian cortex, OCs: ovarian cysts, 
CL: corpus luteum. Dissecting microscope, 25X. 
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• Subgroup-I (TP-treated group): 
The main histological features of the ovaries in this group had been illustrated as follows: total 
absence of corpora lutea, large cortical cysts (5-8 in number) with their cavities containing 
remnants of antral fluid and scattered degenerated and necrotic granulosa cells could be seen. 
These numbers were statistically (p<0.05) higher than those of control group. The walls of these 
cysts were formed by layers of ovarian stroma that failed to differentiate into theca interna and 
theca externa layers. Theca interna cellular layers were highly significant (p<0.01) less in number 
(or even absent) than those in control group. The numbers of small cysts revealed highly significant 
(p<0.01) increment in comparison with the control group; however, their sizes were larger than 
those of the control one. Primary and secondary/mature follicles were highly significantly (p<0.01) 
less in number than the control one. The interstitial glands occupied the major part of the stroma 
(84%) which was significantly more than normal stroma (fig. 2-a).  
• Subgroup-II (MET-treated group) and subgroup-III (ANA-treated group): 
The histological findings in these two subgroups will be demonstrated together in comparison and 
illustrated together as figures, since the aim of this study is to compare between the effect of 
metformin and anastrozole on PCOS. 
The following table (table-2) compares between the histological changes elicited in the ovaries of 
MET-treated animals and ANA-treated animals. 
 
Table-2: Histological findings seen in MET-treated and ANA-treated subgroups 
MET-treated subgroup ANA-treated subgroup 
1. Primary and secondary/mature follicles revealed 
significant increase in number in comparison 
with TP-treated group, but still significantly less 
than their numbers in normal ovaries (p < 0.05). 
2. The corpora lutea developed in 3 animals out of 
the 7 animals involved in this subgroup. 
3. Small cysts were more than control group, 
although this increment was statistically 
insignificant. 
 
4. The number of large cortical cysts was more 
than that in the normal ovary; however, this 
increase was statistically insignificant, but 
statistically significant if compared with the TP-
treated subgroup. 
5. Theca interna surrounding large follicles, was 
made of up to (3-4) cellular layers, which were 
still significantly lower than that of control 
group. However, the number of theca layers 
revealed highly significant improvement 
compared with that of TP-treated group (fig. 2-
b). 
1. Primary and secondary/mature follicles were 
almost similar in number to those in the control 
group. However, they were significantly higher 
in number that those in MET-treated group            
(p < 0.05). 
2. The corpora lutea were obviously identified in 
the ovaries of all of the 7 animals involved in 
this subgroup. 
3. The small cysts were less in number than those 
in MET-treated group, yet this decrement was 
statistically insignificant. 
4. The number of large cortical cysts was more or 





5. Theca interna cellular layers were almost 
identical to those seen in control group, and 
significantly more developed than those seen in 
MET-treated group. It was formed by 5-6 
cellular layers (fig. 2-c). 
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All the results (morphological, morphometic & histological) obtained in TP-treated subgroup I were in line with 
the picture of PCOS. The explanation for these changes is attributed to the excessive exogenous androgen 
administration that was injected to the animals of this subgroup. There is one exception that the ovary reduced in 
size in PCOS of this study, this due to the fact that in rodent the ovarian medullary size represents very small 
percentage in comparison with the cortex (Shirai et al, 2009).  This leads to disturbance of normal physiological 
sex hormonal cycle leading to reduction of FSH and then estrogen levels which, in turn, leads to failure of 
maturation of primary follicles into secondary & the mature graafian follicles (Marx and Metha, 2003). This 
explains the presence of large number of small cysts & large cysts (Pradeep et al, 2002), since primary follicles 
will failed to be mature till reaching graafian follicle (Ingraham et al, 2000) & the process is limited to the 
increase in the size of primary follicles forming small cysts which in turn increase in size due to accumulation of 
a great amount of fluid forming large cysts. The enlargement, in turn, occurs on the expanse of the surrounding 
granulosa and theca interna cells leading to degeneration and necrosis of the cells of both layers & thinning or 
absence of theca layers. 
The absence of corpora lutea reflected the failure of the ovulation due to disturbances of feedback 
mechanism between ovary & pituitary gland leading to hormonal imbalance (LH/FSH) (Serafini et al, 1986; 
Spinder et al, 1989). In another word, these histological changes occurred are the mirror to the disturbance of 
normal physiological sequence of sexual hormone from the ovary &pituitary gland due to increase in the level of 
androgen in the blood of the animal of this subgroups. 
Regarding the morphological, morphometric and histological changes in the ovaries of the 
experimental subgroups II and III (which had been treated with metformin and anastrozole respectively), it was 
clear that the improvements in the polycystic ovaries had been observed on using these two therapeutic agents, 
although, the degree of these improvements varied according to which drug had been used.  
The results elicited in ANA-treated subgroup of this study reflected restoration of almost the normal 
development of the ovary in the induced PCOS, which was much better than what occurred on using metformin 
treatment. This difference in response of the ovary to each administered drug, could be attributed to the mode of 
action of each drug on the polycystic ovary. 
Before discussing the effect of metformin or anastrazole on the PCOS, it is better to understand the 
normal physiological sex hormonal cycle. The theca cell is the main source for androgen production in addition 
to the interstitial cells, which in turn under the cover and effect of FSH, will converted into estrogen by the 
action of aromatase enzyme. In the same time androgen production is under the effect of LH hormone. Estrogen 
hormone is the principle effector in maturation of the primary follicle till reaching mature graafian follicle (Attia 
et al, 2001). 
Accordingly, disturbance of this normal physiological cycle will lead to failure of maturation of 
primary follicle (i.e. leading to increase in the number of primary follicle) and this lead to reduction in the 
number or even absence of mature follicle and replace by large cyst (Marx and Metha, 2003) which increase in 
Figure 2: The histological features of the ovary in subgroups TP-treated 
(a), MET-treated (b), and ANA-treated (c). 1⁰F: primary follicle, 2⁰F: 
secondary follicle, MF: mature follicle, CL: corpus luteum, OCs: ovarian 
cysts (cystic follicles), arrow heads: small cysts. H&E, 40X. 
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size on the expanse of the surrounding granulosa cellular layer. This accompanied with failure of ovulation i.e. 
absence of corpous luteum (Serafini et al, 1986). Besides, interstitial cellular bulk will increase in comparison to 
the total ovarian tissue since it considers as one of the principle source of androgen production inside the ovary. 
From this brief review of hormonal physiology the question arises: whether the hyperandrogenemia 
and LH/FSH imbalance are the cause or the result of PCOS?    
The treatment of PCOS via using metformin therapy, may be attributed to its systemic effect in 
lowering insulin level and so reducing androgen production (Ehrmann, 2005; Kabiri et al, 2014), or due to its 
direct effect on reducing androgen synthesis from ovarian tissue (Attia et al, 2001) and then inhibition of 
estradiol production (Mansfield et al, 2003). All this, in sequence, resumes almost normal FSH and LH secretion 
from the pituitary gland (Attia et al, 2001; Mansfield et al, 2003). Other possible explanation of the effect of 
metformin on PCOS is the reduction of ovarian stromal fibrosis seen in PCOS which acts as an obstacle against 
the rupture of mature follicles (Zhang et al, 2013).  
However using metformin, as a therapy for PCOS, did not restor the hormonal physiological cycle in 
the body to the normal status but partially. Since histology of the ovary reflects the hormonal status and in this 
subgroup ovarian histology did not return to the normal one, so this means that the hormonal condition did not 
reach the reasonable level.     
Regarding anastrozole, which is one of the aromatase enzyme inhibitors, its action results in the 
reduction or even cessation of estradiol synthesis. This action could occur directly through its effect on granulosa 
cells to reduce secretion of androgen, or indirectly through inhibition of conversion of the androgen into estrogen 
(Simpson, 2003). This will stimulate FSH secretion through negative feedback mechanism stimulating pituitary 
gland to secret this hormone, which in turn stimulate estrogen secretion from the ovary. This action can resume 
the normal hormonal feedback mechanism between the ovary and the pituitary gland, which results in increase 
secretion of level of FSH. In another words, anastrozole acts to resume the normal physiological cycle of 
pituitary gonadotropins which is disturbed in PCOS. The same results had been elicited by Shiari et al (2008) 
and Radwan (2010). Anastrozole can resume secretion of FSH and so LH/FSH ratio and restor the level of 
estrogen and progesterone to almost normal level and this is proved by reaching to almost normal ovarian 
histology as demonstrated in this study.    
From the results obtained in this research with the discussion of these results, one can conclude that 
anastrozole is superior to metformin in the treatment of PCOS. 
 
6. Recommendation 
To solidify these results with their discussion, it is recommended to do hormonal assay including estrogen, 
progesterone, androgen, FSH and LH when each drug (used in this research) is used as a line of therapy.   
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